Doxorubicin in lymphoma: Association between pharmacokinetic variability and clinical response

Therapeutic Drug Monitoring

Volumn 32, Issue 1, 2010, Pages 50-52

  Elis, Avishay ^a,b   Lishner, Michael ^a,b   Walker, Scott ^c,d   Atias, Dina ^e,f   Korenberg, Avraham ^b,f   Koren, Gideon ^d,g  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^f ASSAF HAROFEH MEDICAL CENTER   (Israel)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Clinical response; Doxorubicin; Hodgkin lymphoma; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MALE; PRIORITY JOURNAL;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; COHORT STUDIES; DOXORUBICIN; DRUG MONITORING; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75649088889     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181c3a16d     Document Type: Article

References (12)

1. Robert J, Vrignaud P, Iliadis A, et al. Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas. Nouv Rev Fr Hematol. 1983;25:9195.
2. Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res. 1983;43:4467-4469.
3. Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol. 2003;51:395-402.
4. Eksborg S, Strandler HS, Edsmyr F, et al. Pharmacokinetic study of i.v. infusions of adriamycin. Eur J Clin Pharmacol. 1985;28:205-212.
5. Richly H, Grubert M, Scheulen ME, et al. Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx-trade mark/Doxil(R) in patients with hematological tumors. Int J Clin Pharmacol Ther. 2009;47:55-57.
6. Camaggi CM, Comparsi R, Strocchi E, et al. HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids. Cancer Chemother. Pharmacol. 1988;21:216-220.
7. Piscitelli SC, Rodvold KA, Rushing DA, et al. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther. 1993;53:555-561.
8. Leca FR, Marchiset-Leca D, Galeani A, et al. Pharmacokinetic- pharmacodynamic relationships between pirarubicin exposure and hematotoxicity; clinical application using only one blood sample. Anticancer Drugs. 1998;9:503-509.
9. Robert J, Illiadis A, Hoerni B, et al. Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol. 1982;18:739-745.
10. Fan L, Goh BC, Wong CI, et al. Genotype of human carbonyl reductase CBR3 correlations with doxorubicin disposition and toxicity. Pharma-cogenet Genomics. 2008;18:621-631.
11. Ratain MJ, Vogelzang NJ, Sinkule JA. Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther. 1987;41:61-67.
12. Rahmani R, Samak R, Bore P, et al. Clinical pharmacokinetics of vinca alkaloids. Bull Cancer. 1988;75:195-200.